Academic And Community Cancer Research United

This trial tests whether adding acalabrutinib—a targeted drug that blocks a key enzyme in cancer cells—to a standard chemotherapy cocktail (modified VR-CAP) can improve outcomes for people with mantle cell lymphoma who are eligible for a stem cell transplant. The study enrolls ad…

This phase 2 trial tests whether combining the targeted drug regorafenib with the immunotherapy durvalumab can shrink high-risk liver cancer before surgery. The study enrolled 4 adults with stage IB to IIIA hepatocellular carcinoma. Researchers are measuring how many patients see…

This phase 2 trial tests whether a vaccine made from a protein found on many triple-negative breast cancer cells can help prevent the cancer from coming back. Participants receive the vaccine along with an immune booster and a low dose of chemotherapy. The study includes women wi…

This study tests a drug called olaparib in 32 people with advanced bile duct cancer that has spread and has certain DNA repair gene mutations. Olaparib works by blocking enzymes that cancer cells need to grow. The main goal is to see how many patients are alive without their canc…

This study tests a personalized approach for people with early-stage Hodgkin lymphoma. Doctors use PET scans to decide if standard chemotherapy alone is enough or if adding immunotherapy drugs can improve results. The goal is to boost survival while limiting unnecessary treatment…

This phase 2 trial is testing a combination of two drugs—nivolumab and brentuximab vedotin—in 46 older adults (60+) or those unable to receive standard chemotherapy for untreated Hodgkin lymphoma. The goal is to see if this immunotherapy-based approach can shrink or eliminate tum…

This phase II trial tests whether a natural supplement called PEA can relieve nerve pain, numbness, and tingling caused by chemotherapy in cancer patients. About 88 adults who have had nerve symptoms for at least 3 months after chemo will take PEA or a placebo for 8 weeks. The st…